Of note, ABCP significantly improved PFS (HR, 0.41; 95% CI: 0.22–0.78) for the patients with EGFR exon19 deletion or L858R mutation compared to BCP in the subgroup analysis [73], showing that the ABCP therapy may be beneficial for EGFR-mutated NSCLC patients. This evidence concerns the gene ABCG2 and non-small cell lung carcinoma.